These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28066929)

  • 1. Diagnostic work-up of acute myeloid leukemia.
    Weinberg OK; Sohani AR; Bhargava P; Nardi V
    Am J Hematol; 2017 Mar; 92(3):317-321. PubMed ID: 28066929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukaemia: How to combine multiple tools.
    Merino A; Boldú L; Ermens A
    Int J Lab Hematol; 2018 May; 40 Suppl 1():109-119. PubMed ID: 29741260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
    Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
    Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
    Chen X; Cherian S
    Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparameter flow cytometry in the diagnosis and management of acute leukemia.
    Peters JM; Ansari MQ
    Arch Pathol Lab Med; 2011 Jan; 135(1):44-54. PubMed ID: 21204710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease in acute myelogenous leukemia.
    Raanani P; Ben-Bassat I
    Acta Haematol; 2004; 112(1-2):40-54. PubMed ID: 15179004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphology and classification of acute myeloid leukemias.
    Krause JR
    Clin Lab Med; 2000 Mar; 20(1):1-16. PubMed ID: 10702892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukemia.
    Schumacher HR; Alvares CJ; Blough RI; Mazzella F
    Clin Lab Med; 2002 Mar; 22(1):153-92, vii. PubMed ID: 11933574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia].
    Heilmeier B; Buske C; Spiekermann K; Bohlander S; Feuring-Buske M; Hiddemann W; Braess J
    Med Klin (Munich); 2007 Apr; 102(4):296-308. PubMed ID: 17426933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.